0001140361-22-010439 | 20-F | XBRL Viewer

aciu_ProceedsFromIssueOfConvertibleDebt

SFr 23,463,000

aciu_ProceedsFromIssueOfConvertibleDebt

aciu_ProceedsFromIssueOfConvertibleDebt

SFr 50,278,000

aciu_ProceedsFromIssueOfConvertibleDebt

SFr 25,000,000

Research and development expense allocation, wages and salaries

aciu_ProceedsFromIssueOfConvertibleDebt

SFr 23,500,000

aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries

16,465,000

Research and development expense allocation, wages and salaries

aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries

14,424,000

Research and development expense allocation, wages and salaries

aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries

12,382,000

Research and development expense allocation, operating expense

aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense

44,289,000

Research and development expense allocation, operating expense

aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense

43,787,000

Research and development expense allocation, operating expense

aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense

37,465,000

aciu_CurrentAccruedResearchAndDevelopmentCosts

aciu_CurrentAccruedResearchAndDevelopmentCosts

10,361,000

aciu_CurrentAccruedResearchAndDevelopmentCosts

5,298,000

Employee, full-time equivalents in research and development

aciu_CurrentAccruedResearchAndDevelopmentCosts

SFr 3,700,000

aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment

108.6

Employee, full-time equivalents in research and development

aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment

115.3

Employee, full-time equivalents in research and development

aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment

102.7

Fair value of financial assets and liabilities [Policy Text Block]

aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock

Fair value of financial assets and liabilities

The Company’s financial assets and liabilities are composed of receivables, short-term financial assets, cash and cash equivalents, trade payables and lease liabilities. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments, and are held at their amortized cost in accordance with IFRS 9, unless otherwise explicitly noted.

Receivables

Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor’s inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with these receivables held at amortized cost.

Short-term financial assets

Short-term financial assets are held with external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 through 12 months in duration.

The Company assesses whether there is objective evidence that financial assets are impaired annually or whenever potential impairment triggers may occur.

Cash and cash equivalents

Cash and cash equivalents include deposits held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with original duration of less than 3 months.

Trade payables

Trade payables are amounts due to third parties in the ordinary course of business.

Increase in number of ordinary shares issued under conversion of convertible debt

aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt

3,026,634

Increase in number of ordinary shares issued under conversion of convertible debt

aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt

Increase in number of ordinary shares issued under conversion of convertible debt

aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt

1,513,317

Increase in number of ordinary shares issued under conversion of convertible debt

aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt

1,513,317

Increase in number of ordinary shares issued under conversion of convertible debt

aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt

3,026,634

Potential number of shares issued from issue of equity instruments

aciu_PotentialNumberOfSharesIssuedFromIssueOfEquityInstruments

1,551,413

Contract assets, additions

aciu_ContractAssetsAdditions

SFr 1,635,000

Contract assets, additions

aciu_ContractAssetsAdditions

2,354,000

Interest income, net defined benefit liability (asset)

aciu_InterestIncomeNetDefinedBenefitLiabilityAsset

48,000

Interest income, net defined benefit liability (asset)

aciu_InterestIncomeNetDefinedBenefitLiabilityAsset

42,000

Interest income, net defined benefit liability (asset)

aciu_InterestIncomeNetDefinedBenefitLiabilityAsset

133,000

Interest income, net defined benefit liability (asset)

aciu_InterestIncomeNetDefinedBenefitLiabilityAsset

48,000

Interest income, net defined benefit liability (asset)

aciu_InterestIncomeNetDefinedBenefitLiabilityAsset

42,000

Interest income, net defined benefit liability (asset)

aciu_InterestIncomeNetDefinedBenefitLiabilityAsset

133,000

Contract assets, deductions

aciu_ContractAssetsDeductions

2,251,000

Contract assets, deductions

aciu_ContractAssetsDeductions

1,858,000

Potential increase is equity through issue of equity instruments

aciu_PotentialIncreaseIsEquityThroughIssueOfEquityInstruments

31,028,260

General and administrative expense allocation, expense from share-based payment transactions with employees

aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees

2,598,000

General and administrative expense allocation, expense from share-based payment transactions with employees

aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees

2,812,000

General and administrative expense allocation, expense from share-based payment transactions with employees

aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees

SFr 2,249,000

Number of other equity instruments expired or forfeited in share-based payment arrangement

aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement

19,632

Income tax loss, Carryforward period

aciu_IncomeTaxLossCarryforwardPeriod

7 years

Revenue reclassified to other income (expense)

aciu_RevenueReclassifiedToOtherIncomeExpense

SFr 0

Revenue reclassified to other income (expense)

aciu_RevenueReclassifiedToOtherIncomeExpense

300,000

Revenue reclassified to other income (expense)

aciu_RevenueReclassifiedToOtherIncomeExpense

600,000

Interest cost, net defined benefit liability (asset)

aciu_InterestCostNetDefinedBenefitLiabilityAsset

79,000

Interest cost, net defined benefit liability (asset)

aciu_InterestCostNetDefinedBenefitLiabilityAsset

71,000

Interest cost, net defined benefit liability (asset)

aciu_InterestCostNetDefinedBenefitLiabilityAsset

195,000

Interest cost, net defined benefit liability (asset)

aciu_InterestCostNetDefinedBenefitLiabilityAsset

79,000

Interest cost, net defined benefit liability (asset)

aciu_InterestCostNetDefinedBenefitLiabilityAsset

71,000

Interest cost, net defined benefit liability (asset)

aciu_InterestCostNetDefinedBenefitLiabilityAsset

SFr 195,000

Number of other equity instruments exercised in share-based payment arrangement

aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement

84,638

Number of other equity instruments exercised in share-based payment arrangement

aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement

2,471

Description of accounting policy for accounting judgments and estimates [Policy Text Block]

aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock

Critical judgments and accounting estimates

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.

The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on LCAs, (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) income taxes, (v) share-based compensation, (vi) right-of-use assets and lease liabilities and (vii) our IPR&D asset. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Contract liabilities, addition

aciu_ContractLiabilitiesAddition

SFr 1,635,000

Contract liabilities, addition

aciu_ContractLiabilitiesAddition

SFr 1,467,000

Defined benefit plan, percentage of contribution

aciu_DefinedBenefitPlanPercentageOfContribution

47.00%

Defined benefit plan, percentage of contribution

aciu_DefinedBenefitPlanPercentageOfContribution

53.00%

Contract liabilities, deductions

aciu_ContractLiabilitiesDeductions

SFr 1,224,000

Contract liabilities, deductions

aciu_ContractLiabilitiesDeductions

SFr 5,638,000

Operating segments, number

aciu_OperatingSegmentsNumber

Increase (decrease) in plan assets of defined benefit plan, amount

aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount

SFr 1,200,000

Disclosure Of Accounting Policy For Changes In Accounting Policies Recently Adopted [Text Block]

aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock

Accounting policies, new standards, interpretations and amendments adopted by the Company

The Company has not adopted any standard, interpretation or amendment that has been issued but is not yet effective. Such standards are not currently expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

Increase (decrease) in plan assets of defined benefit plan, percentage

aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage

10.00%

Reportable segments, number

aciu_ReportableSegmentsNumber

Disclosure of right-of-use assets impact on statements [Text Block]

aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock

For the years ended December 31, 2021, and 2020, the impact on the Company’s consolidated statements of income/(loss) and consolidated statements of cash flows is detailed in the table below.

	For the Years Ended December 31,
In CHF thousands	2021		2020
Consolidated statements of income/(loss)
Depreciation of right-of-use assets		509		432
Interest expense on lease liabilities		63		53
Expense for short-term leases and leases of low value		723		603
Total		1,295		1,088
Consolidated statements of cash flows
Total cash outflow for leases		1,299		1,088

Weighted average exercise price of other equity instruments exercised in sharebased payment arrangement2019

aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019

SFr 9.51

Weighted average exercise price of other equity instruments exercised in sharebased payment arrangement2019

aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019

SFr 9.46

aciu_ConvertibleBorrowings

SFr 12,500,000

aciu_ConvertibleBorrowings

SFr 11,700,000

aciu_ConvertibleBorrowings

SFr 12,500,000

Sale or issue of treasury shares, shares

aciu_ConvertibleBorrowings

SFr 11,700,000

aciu_SaleOrIssueOfTreasurySharesShares

Sale or issue of treasury shares, shares

aciu_SaleOrIssueOfTreasurySharesShares

1,171,543

Sale or issue of treasury shares, shares

aciu_SaleOrIssueOfTreasurySharesShares

1,171,543

aciu_CollaborativeAgreementPotentialValue

SFr 60,000,000

aciu_CollaborativeAgreementPotentialValue

SFr 340,000,000

aciu_CollaborativeAgreementPotentialValue

SFr 314,000,000

aciu_CollaborativeAgreementPotentialValue

400,000,000

aciu_CollaborativeAgreementPotentialValue

SFr 500,000,000

aciu_CollaborativeAgreementPotentialValue

SFr 160,000,000

aciu_CollaborativeAgreementPotentialValue

SFr 167,000,000

aciu_CollaborativeAgreementPotentialValue

SFr 3,200,000

aciu_CollaborativeAgreementPotentialValue

SFr 3,000,000.0

aciu_CollaborativeAgreementPotentialValue

SFr 1,500,000

aciu_CollaborativeAgreementPotentialValue

SFr 1,400,000

aciu_CollaborativeAgreementPotentialValue

SFr 300,000

Collaborative agreement, milestone payment, number of installments

aciu_CollaborativeAgreementPotentialValue

SFr 200,000

aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments

Collaborative agreement, milestone payment, number of installments

aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments

General and administrative expense allocation, wages and salaries

aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries

SFr 8,281,000

General and administrative expense allocation, wages and salaries

aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries

8,274,000

General and administrative expense allocation, wages and salaries

aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries

7,172,000

Current receivables classified as other and value added and withholding taxes

aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes

428,000

Current receivables classified as other and value added and withholding taxes

aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes

329,000

Gain (loss) arising from change in fair value of convertible instrument

aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument

Gain (loss) arising from change in fair value of convertible instrument

aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument

Gain (loss) arising from change in fair value of convertible instrument

aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument

SFr 4,542,000

Disclosure of detailed information about trade payables and accrued liabilities [Table Text Block]

aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock

	As of December 31,
In CHF thousands	2021		2020
Trade and other payables		2,003		2,184
Total trade and other payables		2,003		2,184

Accrued research and development costs		10,361		5,298
Accrued payroll expenses		3,562		3,494
Accrued stamp duty		778		—
Accrued liabilities		952		686
Other accrued expenses		1,083		1,607
Total accrued expenses		16,736		11,085

Percentage of Accrued Income

aciu_PercentageOfAccruedIncome

87.00%

Percentage of Accrued Income

aciu_PercentageOfAccruedIncome

68.10%

Collaborative agreement, Collaboration contract receivable for regulatory, commercialization and sales milestones

aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones

SFr 148,000,000

Collaborative agreement, Collaboration contract receivable for regulatory, commercialization and sales milestones

aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones

SFr 155,000,000

Issuance of shares for purchase of IPR&D asset in asset acquisition

aciu_IssuanceOfSharesForPurchaseOfIPRDAssetInAssetAcquisition

50,416,000

Issuance of shares for purchase of IPR&D asset in asset acquisition

aciu_IssuanceOfSharesForPurchaseOfIPRDAssetInAssetAcquisition

Issuance of shares for purchase of IPR&D asset in asset acquisition

aciu_IssuanceOfSharesForPurchaseOfIPRDAssetInAssetAcquisition

SFr 0

Increase (decrease) through treasury share transactions, equity, shares

aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares

5,000,000

Increase (decrease) through treasury share transactions, equity, shares

aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares

(5,000,000)

Increase (decrease) through treasury share transactions, equity, shares

aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares

2,393,160

Increase (decrease) through treasury share transactions, equity, shares

aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares

(2,393,160)

Vesting requirements for share-based payment arrangement, award vesting period

aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod

4 years

Vesting requirements for share-based payment arrangement, award vesting period

aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod

1 year

Vesting requirements for share-based payment arrangement, award vesting period

aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod

3 years

Vesting requirements for share-based payment arrangement, award vesting period

aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod

4 years

Vesting requirements for share-based payment arrangement, award vesting period

aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod

4 years

Vesting requirements for share-based payment arrangement, award vesting period

aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod

1 year

Vesting requirements for share-based payment arrangement, award vesting period

aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod

4 years

aciu_ShareOptionsDateOfExpiry

2022

aciu_ShareOptionsDateOfExpiry

2026

aciu_ShareOptionsDateOfExpiry

2027

aciu_ShareOptionsDateOfExpiry

2028